ANAVEX LIFE SCIENCES | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (52)

View All

Latest Posts

About This Stock More About This Stock
Top Picks For 2023: Anavex Life Sciences
Article By: MoneyShow.com
Friday, January 6, 2023 1:40 PM EDT
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett Syndrome. Let's see why it's a favorite for 2023.
In this article: AVXL Also: BIIB
Read
Anavex: Alzheimer's To Parkinson's Dementia
Article By: MoneyShow.com
Friday, April 15, 2022 10:17 AM EDT
Following a huge gain in 2021 (after a big gain in 2020), the shares have given back 27% year-to-date as investors ride out a quiet stretch awaiting trial results.
In this article: AVXL
Read
Alzheimer's Disease: 5 Stocks On Biotech Radars
Video By: Kevin Cook
Thursday, April 22, 2021 7:53 PM EDT
What's been interesting for the past couple of years, and especially the last few months, is to watch the rise of emerging, small-cap Biotech companies trying to take on the big AD and other neurological and CNS diseases.
In this video: AVXL, JAZZ, BIIB, AXSM, SAVA
Watch
Top Picks 2020: Anavex
Article By: MoneyShow.com
Saturday, January 11, 2020 9:00 PM EDT
This little known, yet promising, bio-pharmaceutical company is worthy of a closer look.
In this article: AVXL
Read
Healthcare Investing Ideas Big And Small
Article By: Marc Lichtenfeld
Monday, January 15, 2018 9:00 PM EDT
With a dire need for growth, many in the industry expect the larger biotech and pharmaceutical companies to open their wallets and acquire smaller companies with novel drugs in development.
In this article: BMY, GSK, JNJ, PFE, AVXL, IMMP, BMRN, FOLD, SGEN, MBOT
Read
All Posts

Latest Tweets for $AVXL

No tweets yet!

PARTNER HEADLINES